References
- GorevskiEBianBKeltonCMMartin BooneJEGuoJJEvidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination SurveyValue Health2012151323822264969
- FuksaLVocelkaMVytrisalovaMThe impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997–2013Health Policy201511991255126425929214
- ManovaMStoimenovaASavovaAPeikovPPetrovaGUtilization and price trends in some reimbursed cardiovascular medicinesBiotechnol Biotechnol Equip201125224242431
- VojvodićZStimacDTrends in statin consumption and cardiovascular mortality in Croatia 2004–2012Coll Antropol201438suppl 2737825643531
- CollinsRArmitageJParishSSleighPPetoRHeart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trialLancet200336193742005201612814710
- GodmanBBakerALeporovskiAInitiatives to increase the prescribing of low cost generics; the case of Scotland in the international contextMed Res Arch201753134
- LittmanJHalilRPotential effects of rational prescribing on national health care spending: more than half a billion dollars in annual savingsCan Fam Physician201662323524426975917
- WengTCYangYHLinSJTaiSHA systematic review and meta-analysis on the therapeutic equivalence of statinsJ Clin Pharm Ther201035213915120456733
- PedersenTRFaergemanOKasteleinJJIncremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954 Erratum inJAMA2005294243092
- BennieMGodmanBBishopICampbellSMultiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in ScotlandExpert Rev Pharmacoecon Outcomes Res201212112513022280202
- PrescQIPPSwitching Rosuvastatin to Atorvastatin2014 Bulletin81Accessed March 6, 2018
- Usher-SmithJRamsbottomTPearmainHKirbyMEvaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years onInt J Clin Pract200862348048418201178
- FraeymanJVan HalGGodmanBBeutelsPThe potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in BelgiumExpert Rev Pharmacoecon Outcomes Res201313114115123402454
- SimoensSSinnaevePRPatient co-payment and adherence to statins: a review and case studiesCardiovasc Drugs Ther20142819910924150747
- WHO Collaborating Centre for Drug Statistics MethodologyATC/DDD index 20182018 Available from: https://www.whocc.no/atc_ddd_index/Accessed April 30, 2018
- WHO Collaborating Centre for Drug Statistics Methodology [webpage on the Internet] Available from: http://www.whocc.no/atcdddindex_Accessed September 22, 2014
- VancheriFBacklundLStrenderLEGodmanBWettermarkBTime trends in statin utilisation and coronary mortality in Western European countriesBMJ Open201663e010500
- MartikainenJESaastamoinenLKKorhonenMJEnlundHHelin-SalmivaaraAImpact of restricted reimbursement on the use of statins in Finland: a register-based studyMed Care201048976176620706164
- SakshaugSFuruKKarlstadØRønningMSkurtveitSSwitching statins in Norway after new reimbursement policy: a nationwide prescription studyBr J Clin Pharmacol200764447648117441934
- GodmanBSchwabeUSelkeGWettermarkBUpdate of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugsPharmacoeconomics200927543543819586083
- DamianiGFedericoBAnselmiAThe impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysisBMC Health Serv Res201414624393340
- GodmanBShrankWAndersenMComparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implicationsExpert Rev Pharmacoecon Outcomes Res201010670772221155704
- BaeGParkCLeeHHanEKimDSJangSEffective policy initiatives to constrain lipid-lowering drug expenditure growth in South KoreaBMC Health Serv Res20141410024589172
- EichlerKZollerMTschudiPSteurerJBarriers to apply cardiovascular prediction rules in primary care: a postal surveyBMC Fam Pract20078117201905
- Croatian Institute for Public HealthCroatian health-statistical annals, 1990–2012ZagrebCroatian Institute for Public Health19912013 Croatian
- DelijaIVrdoljakDBergman-MarkovikjBHow well do family physicians record cardiovascular risk factors?Med Jadertina2012423–4129137
- FerrajoloCArcoraciVSulloMGPattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?PLoS One201497e10214625072244
- Health Insurance Fund of Macedonia [webpage on the Internet]Annual reports for the expenditures in denars for the drugs that are on the positive list in The Republic of Macedonia Available from: http://genet.sickkids.on.ca/appAccessed May 28, 2018 Macedonian